Stocks · News reference
8-K filing — Camp4 Therapeutics Corp (CAMP)
Filed: 2026-08-04 AccNo: 0001628280-26-052150 Size: 531 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 4, 2026, 11:10 AM
- Checked
- Aug 4, 2026, 11:10 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15
Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and raises the price target from $12 to $15.
Read original at benzingaCamp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.21) by 176.19 percent. This is a 6.45 percent increase over losses of $(0.62) per share
Read original at benzinga8-K filing — Camp4 Therapeutics Corp (CAMP)
Filed: 2026-08-13 AccNo: 0001628280-26-056758 Size: 262 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar